Nomura Upgrades Intercept Pharmaceuticals to Positive (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by research analysts at Nomura to a “positive” rating in a report released on Tuesday. The firm currently has a $456.00 price target on the stock. Nomura’s target price would suggest a potential upside of 92.26% from the company’s current price.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 322.713 on Tuesday. Intercept Pharmaceuticals has a 52 week low of $42.41 and a 52 week high of $497.00. The stock’s 50-day moving average is $232.5 and its 200-day moving average is $291.8. The company’s market cap is $6.805 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Monday, August 11th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. On average, analysts predict that Intercept Pharmaceuticals will post $-14.82 earnings per share for the current fiscal year.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski unloaded 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $226.72, for a total value of $2,267,200.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
ICPT has been the subject of a number of other recent research reports. Analysts at RBC Capital raised their price target on shares of Intercept Pharmaceuticals from $425.00 to $500.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. Separately, analysts at Leerink Swann upgraded shares of Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday. They now have a $445.00 price target on the stock, up previously from $270.00. Finally, analysts at Deutsche Bank upgraded shares of Intercept Pharmaceuticals to an “outperform” rating in a research note on Tuesday. They now have a $500.00 price target on the stock, up previously from $395.00. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Intercept Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $503.00.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.